Earnings playRegeneron Pharmaceuticals, Inc.BATS:REGNWSMS199REGN’s chart shows a classic dip in a long-term uptrend, with FDA tailwinds and undervaluation (14x PE vs. sector 25x) making it a compelling buy. The $560–$570 zone offers a low-risk entry ahead of earnings, where a beat could ignite a 20–30% rally to $700+. Buy on dip for 10–15% short-term gain, with 20–30% upside post-earnings if catalysts hit Oct 28. Eps will be lower due to $83 million acquired in-process R&D charge. Some caution on Eylea erosion, but sentiment leans bullish, tight risk management advised.